Cancer treatment today looks nothing like it did 40 years ago. Around 40% of cancers are preventable and around 80% of patients treated survive 10 years or more. To move forward, there are two particular issues that are longstanding and seemingly intractable. The first relates to many aggressive cancers have known etiologies, e.g. mutations or amplifications of RAS or MYC, or recurrent chromosomal translocations that lead to generation of fusion oncoproteins such as EWS-FLI1 or PAX-FOXO. However, these cancers remain without an effective treatment because there are no effective inhibitors for the cancer-specific targets. The development of inhibitors or the identification of cancer-specific dependencies that are directly or indirectly linked to the intractable oncogenic targets are urgently needed. Second, the treatment of metastasized cancers has not advanced significantly; often they are beyond successful treatment, e.g. metastatic triple-negative breast cancer. The cancer stem cells that sustain cancer are largely the cause of metastasis and relapse. They are spared by chemotherapy and radiotherapy, and there is, therefore, the need to develop therapies to eliminate these cells.
The special issue welcomes original work that addresses the development of specific inhibitors to intractable oncoprotein targets or their downstream targets, identify the upstream or downstream dependencies that are directly or indirectly linked to intractable oncoprotein targets, targeting interaction partners or regulators of oncoprotein targets that creates vulnerabilities, and identifying oncogenic mechanisms of intractable oncoproteins. The special issue also welcomes manuscripts that address targets that are important to eliminating cancer stem cells. All manuscripts will be peer-reviewed with the goal of disseminating novel and reproducible dependencies that have potential to be translated rapidly into clinics.
• Development of novel, specific inhibitors to intractable oncoprotein targets
• Identification of vulnerabilities or dependencies that are linked to oncoprotein targets
• Targeting upstream, downstream or interaction partners of intractable oncoproteins that lead to vulnerabilities
• Identifying previously unidentified oncogenic mechanisms of intractable oncoproteins
• Identification of targets for eliminating cancer stem cells
• Original manuscripts that address the above or related issues, and review articles (comprehensive or short) describing the latest advancements in the aforementioned areas are invited to submit their work.
Cancer treatment today looks nothing like it did 40 years ago. Around 40% of cancers are preventable and around 80% of patients treated survive 10 years or more. To move forward, there are two particular issues that are longstanding and seemingly intractable. The first relates to many aggressive cancers have known etiologies, e.g. mutations or amplifications of RAS or MYC, or recurrent chromosomal translocations that lead to generation of fusion oncoproteins such as EWS-FLI1 or PAX-FOXO. However, these cancers remain without an effective treatment because there are no effective inhibitors for the cancer-specific targets. The development of inhibitors or the identification of cancer-specific dependencies that are directly or indirectly linked to the intractable oncogenic targets are urgently needed. Second, the treatment of metastasized cancers has not advanced significantly; often they are beyond successful treatment, e.g. metastatic triple-negative breast cancer. The cancer stem cells that sustain cancer are largely the cause of metastasis and relapse. They are spared by chemotherapy and radiotherapy, and there is, therefore, the need to develop therapies to eliminate these cells.
The special issue welcomes original work that addresses the development of specific inhibitors to intractable oncoprotein targets or their downstream targets, identify the upstream or downstream dependencies that are directly or indirectly linked to intractable oncoprotein targets, targeting interaction partners or regulators of oncoprotein targets that creates vulnerabilities, and identifying oncogenic mechanisms of intractable oncoproteins. The special issue also welcomes manuscripts that address targets that are important to eliminating cancer stem cells. All manuscripts will be peer-reviewed with the goal of disseminating novel and reproducible dependencies that have potential to be translated rapidly into clinics.
• Development of novel, specific inhibitors to intractable oncoprotein targets
• Identification of vulnerabilities or dependencies that are linked to oncoprotein targets
• Targeting upstream, downstream or interaction partners of intractable oncoproteins that lead to vulnerabilities
• Identifying previously unidentified oncogenic mechanisms of intractable oncoproteins
• Identification of targets for eliminating cancer stem cells
• Original manuscripts that address the above or related issues, and review articles (comprehensive or short) describing the latest advancements in the aforementioned areas are invited to submit their work.